Trial Profile
An open label study to investigate the safety and efficacy of abacavir/lamivudine/dolutegravir and the pharmacokinetic profile of dolutegravir in HIV infected patients of 60 years of age and older
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 03 Feb 2020 Results (N=93), analysis of the data pooled from 4 trials(3 phase I studies NCT02219217, NCT02509195 and NCT03094507 and one Phase III NCT02351908) assessing genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics, published in the Journal of Antimicrobial Chemotherapy
- 16 May 2018 Results (n=43) assessing abacavir/lamivudine/dolutegravir in patients with HIV-1 infection, were published in the Clinical Infectious Diseases.
- 28 Feb 2018 Status changed from active, no longer recruiting to completed.